Regenxbio is a Rockville, Maryland–based gene therapy-focused biotech leveraging its proprietary NAV® Technology to develop AAV-based treatments for CNS and retinal diseases, including Hurler Syndrome (MPS I), Hunter Syndrome (MPS II) and wet age-related macular degeneration. Led by President and CEO Ken Mills, the company is advancing its lead programs through clinical development and has granted 16 commercial licenses for NAV Technology-based treatments. Regenxbio intends to use new funds to advance lead programs through clinical development, build out clinical and manufacturing infrastructure, expand its team and add to its pipeline of innovative AAV gene therapies. The company closed a $70.5M Series D round that brought total funding to more than $110M. In conjunction with the financing, Dr. Edgar Engleman, Managing Partner of Vivo Capital, joined Regenxbio’s board of directors. Regenxbio leverages its proprietary NAV® Technology to develop gene therapies targeting central nervous system diseases such as Hurler Syndrome (MPS I) and Hunter Syndrome (MPS II). The company is advancing lead programs through clinical development and has plans to build out clinical and manufacturing infrastructure while expanding its team. Regenxbio formed Dimension Therapeutics with Fidelity Biosciences to focus on NAV-based gene therapies for liver-directed rare diseases. Led by President and CEO Ken Mills, the company is positioning its platform to address multiple diseases where gene therapy can make a meaningful difference. Regenxbio is headquartered in Washington, DC. The company completed a financing to support these development and infrastructure goals.

Total raised

$101M

Funding rounds

2

Latest round

Series D

Latest activity

May 2015